• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Cytek Biosciences Set to Join S&P SmallCap 600

    4/25/23 5:54:00 PM ET
    $ABT
    $CSII
    $CTKB
    $SPGI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $ABT alert in real time by email

    NEW YORK, April 25, 2023 /PRNewswire/ -- Cytek Biosciences Inc (NASD:CTKB) will replace Cardiovascular Systems Inc. (NASD:CSII) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, May 1. S&P 500 and 100 constituent Abbott Laboratories (NYSE:ABT) is acquiring Cardiovascular Systems in a deal expected to be completed soon, pending final closing conditions.

    Following is a summary of the changes that will take place prior to the open of trading on the effective date:

    Effective Date

    Index Name      

    Action

    Company Name

    Ticker

    GICS Sector

    May 1, 2023

    S&P SmallCap 600

    Addition

    Cytek Biosciences

    CTKB

    Health Care



    S&P SmallCap 600

    Deletion

    Cardiovascular Systems

    CSII

    Health Care

    For more information about S&P Dow Jones Indices, please visit www.spdji.com

    ABOUT S&P DOW JONES INDICES

    S&P Dow Jones Indices is the largest global resource for essential index-based concepts, data and research, and home to iconic financial market indicators, such as the S&P 500® and the Dow Jones Industrial Average®. More assets are invested in products based on our indices than products based on indices from any other provider in the world. Since Charles Dow invented the first index in 1884, S&P DJI has been innovating and developing indices across the spectrum of asset classes helping to define the way investors measure and trade the markets.

    S&P Dow Jones Indices is a division of S&P Global (NYSE:SPGI), which provides essential intelligence for individuals, companies, and governments to make decisions with confidence. For more information, visit www.spdji.com.

    FOR MORE INFORMATION:

    S&P Dow Jones Indices

    [email protected]

    Media Inquiries

    [email protected]

    Cision View original content:https://www.prnewswire.com/news-releases/cytek-biosciences-set-to-join-sp-smallcap-600-301807529.html

    SOURCE S&P Dow Jones Indices

    Get the next $ABT alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ABT
    $CSII
    $CTKB
    $SPGI

    CompanyDatePrice TargetRatingAnalyst
    Abbott Laboratories
    $ABT
    7/18/2025$145.00Hold → Buy
    Jefferies
    Abbott Laboratories
    $ABT
    6/16/2025$143.00Market Perform
    Leerink Partners
    Cytek Biosciences Inc.
    $CTKB
    5/9/2025$4.00Buy → Hold
    TD Cowen
    S&P Global Inc.
    $SPGI
    4/10/2025$600.00Buy
    BofA Securities
    S&P Global Inc.
    $SPGI
    3/12/2025$599.00Outperform
    Mizuho
    Cytek Biosciences Inc.
    $CTKB
    1/31/2025$7.00 → $4.50Buy → Sell
    Goldman
    S&P Global Inc.
    $SPGI
    12/20/2024$600.00Buy
    Citigroup
    Abbott Laboratories
    $ABT
    10/8/2024$130.00Outperform
    Oppenheimer
    More analyst ratings

    $ABT
    $CSII
    $CTKB
    $SPGI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Veracyte Set to Join S&P SmallCap 600

      NEW YORK, July 24, 2025 /PRNewswire/ -- Veracyte Inc. (NASD: VCYT) will replace Triumph Group Inc. (NYSE:TGI) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, July 29. Warburg Pincus LLC and Berkshire Partners LLC will acquire Triumph Group in a deal expected to close soon, pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector July 29, 2025 S&P SmallCap 600 Addition Veracyte VCYT Health Care July 29, 2025 S&P SmallCap 600 Deletion Triumph Group TGI Industrials For more information about S&P Dow Jones Indices,

      7/24/25 5:58:00 PM ET
      $SPGI
      $TGI
      $VCYT
      Finance: Consumer Services
      Finance
      Aerospace
      Industrials
    • Methane Emissions Intensity of Permian Basin Declined by More than Half in Two Years, New S&P Global Commodity Insights Analysis Finds

      New analysis provides the most accurate public, basin-wide estimate of methane emissions for the Permian HOUSTON, July 24, 2025 /PRNewswire/ -- The methane intensity of oil and gas production in the Permian Basin—an area responsible for half of U.S. oil production and one fifth of natural gas—declined by more than 50% during the 2022-2024 period as improved operations, better equipment and the utilization of AI and other advanced technologies led to reductions across all observable plume rates (large and small), according to a new analysis by S&P Global Commodity Insights. The

      7/24/25 7:00:00 AM ET
      $SPGI
      Finance: Consumer Services
      Finance
    • Cytek Biosciences to Report Second Quarter 2025 Financial Results on August 6, 2025

      FREMONT, Calif., July 23, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. ("Cytek Biosciences" or "Cytek") (NASDAQ:CTKB), today announced it will report financial results for the second quarter 2025 after market close on Wednesday, August 6, 2025. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. Live audio of the webcast will be available on the "Investors" section of the company website at investors.cytekbio.com About Cytek Biosciences, Inc.Cytek Biosciences (NASDAQ:CTKB) is a leading cell analysis solutions company advancing the next generati

      7/23/25 4:05:00 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $ABT
    $CSII
    $CTKB
    $SPGI
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • October 24, 2023 - FDA Approves New Therapy for Rare Form of Blood Cancers Called Myelodysplastic Syndromes

      For Immediate Release: October 24, 2023 Today, the U.S. Food and Drug Administration approved Tibsovo (ivosidenib) for the treatment of adult patients with relapsed or refractory (R/R) myelodysplastic syndromes (MDS) with an isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. This is the first targeted therapy approved for this indication. The agency also approved the Abbott RealTime

      10/24/23 3:52:17 PM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABT
    $CSII
    $CTKB
    $SPGI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Mccombe William D. bought $97,300 worth of shares (35,000 units at $2.78), increasing direct ownership by 169% to 55,746 units (SEC Form 4)

      4 - Cytek Biosciences, Inc. (0001831915) (Issuer)

      6/3/25 5:39:17 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Jacoby Rebecca bought $8,971 worth of shares (69 units at $130.01), increasing direct ownership by 17% to 469 units (SEC Form 4)

      4 - S&P Global Inc. (0000064040) (Issuer)

      6/17/24 4:04:40 PM ET
      $SPGI
      Finance: Consumer Services
      Finance

    $ABT
    $CSII
    $CTKB
    $SPGI
    SEC Filings

    See more
    • Abbott Laboratories filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - ABBOTT LABORATORIES (0000001800) (Filer)

      7/17/25 7:34:53 AM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 11-K filed by S&P Global Inc.

      11-K - S&P Global Inc. (0000064040) (Filer)

      6/25/25 6:16:08 PM ET
      $SPGI
      Finance: Consumer Services
      Finance
    • SEC Form 8-K filed by Cytek Biosciences Inc.

      8-K - Cytek Biosciences, Inc. (0001831915) (Filer)

      6/24/25 4:05:58 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $ABT
    $CSII
    $CTKB
    $SPGI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Abbott Labs upgraded by Jefferies with a new price target

      Jefferies upgraded Abbott Labs from Hold to Buy and set a new price target of $145.00

      7/18/25 7:54:43 AM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Leerink Partners initiated coverage on Abbott Labs with a new price target

      Leerink Partners initiated coverage of Abbott Labs with a rating of Market Perform and set a new price target of $143.00

      6/16/25 8:17:39 AM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cytek Biosciences downgraded by TD Cowen with a new price target

      TD Cowen downgraded Cytek Biosciences from Buy to Hold and set a new price target of $4.00

      5/9/25 8:41:00 AM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $ABT
    $CSII
    $CTKB
    $SPGI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Stratton John G

      4 - ABBOTT LABORATORIES (0000001800) (Issuer)

      7/1/25 5:32:18 PM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Roman Michael F

      4 - ABBOTT LABORATORIES (0000001800) (Issuer)

      7/1/25 5:24:18 PM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Gonzalez Patricia Paola

      4 - ABBOTT LABORATORIES (0000001800) (Issuer)

      7/1/25 5:13:51 PM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABT
    $CSII
    $CTKB
    $SPGI
    Leadership Updates

    Live Leadership Updates

    See more
    • Veracyte Set to Join S&P SmallCap 600

      NEW YORK, July 24, 2025 /PRNewswire/ -- Veracyte Inc. (NASD: VCYT) will replace Triumph Group Inc. (NYSE:TGI) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, July 29. Warburg Pincus LLC and Berkshire Partners LLC will acquire Triumph Group in a deal expected to close soon, pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector July 29, 2025 S&P SmallCap 600 Addition Veracyte VCYT Health Care July 29, 2025 S&P SmallCap 600 Deletion Triumph Group TGI Industrials For more information about S&P Dow Jones Indices,

      7/24/25 5:58:00 PM ET
      $SPGI
      $TGI
      $VCYT
      Finance: Consumer Services
      Finance
      Aerospace
      Industrials
    • Block Set to Join S&P 500

      NEW YORK, July 18, 2025 /PRNewswire/ -- Block Inc. (NYSE:XYZ) will replace Hess Corp. (NYSE:HES) in the S&P 500 effective prior to the opening of trading on Wednesday, July 23. S&P 500 and S&P 100 constituent Chevron Corp. (NYSE: CVX) has acquired Hess Corp in a deal that closed today, July 18. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name  Action Company Name Ticker GICS Sector July 23, 2025 S&P 500 Addition Block XYZ Financials July 23, 2025 S&P 500 Deletion Hess HES Energy For more information about S&P Dow Jones Indices, please visit www.spdji.com.  ABOUT S&P DOW JONES INDICES S&P Dow Jones Indi

      7/18/25 6:02:00 PM ET
      $CVX
      $HES
      $SPGI
      $XYZ
      Integrated oil Companies
      Energy
      Finance: Consumer Services
      Finance
    • AeroVironment Set to Join S&P MidCap 400; Victory Capital Holdings to Join S&P SmallCap 600

      NEW YORK, July 15, 2025 /PRNewswire/ -- AeroVironment Inc. (NASD: AVAV) will replace ChampionX Corp. (NASD: CHX) in the S&P MidCap 400, and Victory Capital Holdings Inc. (NASD: VCTR) will replace AeroVironment in the S&P SmallCap 600 effective prior to the opening of trading on Friday, July 18. S&P 500 constituent Schlumberger Ltd. (NYSE:SLB) is acquiring ChampionX in a deal expected to be completed July 16, pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector July 18, 2025 S&P MidCap 400 Addition AeroVironment AVAV Industrials J

      7/15/25 5:44:00 PM ET
      $AVAV
      $CHX
      $SLB
      $SPGI
      Aerospace
      Industrials
      Industrial Machinery/Components
      Oilfield Services/Equipment

    $ABT
    $CSII
    $CTKB
    $SPGI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Cytek Biosciences Inc.

      SC 13G - Cytek Biosciences, Inc. (0001831915) (Subject)

      11/14/24 4:35:51 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SC 13G/A filed by Cytek Biosciences Inc.

      SC 13G/A - Cytek Biosciences, Inc. (0001831915) (Subject)

      11/14/24 1:42:15 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G filed by Cytek Biosciences Inc.

      SC 13G - Cytek Biosciences, Inc. (0001831915) (Subject)

      2/22/24 7:07:27 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $ABT
    $CSII
    $CTKB
    $SPGI
    Financials

    Live finance-specific insights

    See more
    • Cytek Biosciences to Report Second Quarter 2025 Financial Results on August 6, 2025

      FREMONT, Calif., July 23, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. ("Cytek Biosciences" or "Cytek") (NASDAQ:CTKB), today announced it will report financial results for the second quarter 2025 after market close on Wednesday, August 6, 2025. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. Live audio of the webcast will be available on the "Investors" section of the company website at investors.cytekbio.com About Cytek Biosciences, Inc.Cytek Biosciences (NASDAQ:CTKB) is a leading cell analysis solutions company advancing the next generati

      7/23/25 4:05:00 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • S&P Dow Jones Indices to Acquire ARC Research, Expanding Wealth Data and Benchmarking Capabilities

      LONDON, July 21, 2025 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI"), a division of S&P Global (NYSE:SPGI) and the world's leading index provider, today announced that it has entered into a definitive agreement to acquire ARC Research, a subsidiary of ARC Group, and the leading independent provider of investment performance data, benchmarking capabilities and insights in the private wealth market. ARC Research maintains the world's largest proprietary dataset of more than 500,000 private client portfolios spanning over two decades. The firm is a trusted partner to more than

      7/21/25 7:00:00 AM ET
      $SPGI
      Finance: Consumer Services
      Finance
    • Abbott Reports Second-Quarter 2025 Results

      Second-quarter reported sales growth of 7.4 percent; organic sales growth of 6.9 percent or 7.5 percent excluding COVID-19 testing-related sales1Second-quarter GAAP diluted EPS of $1.01; adjusted diluted EPS of $1.26Reported gross margin of 52.7 percent of sales; adjusted gross margin of 57.0 percent, which reflects a 100 basis point increaseReported operating margin of 18.4 percent of sales; adjusted operating margin of 22.9 percent, which reflects a 100 basis point increaseABBOTT PARK, Ill., July 17, 2025 /PRNewswire/ -- Abbott (NYSE:ABT) today announced financial results for the second quarter ended June 30, 2025. Second-quarter sales increased 7.4 percent on a reported basis, 6.9 percen

      7/17/25 7:30:00 AM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care